Ben Creelan

Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer

Matthew D. Hellmann, Tavi Nathanson, Hira Rizvi et al. · Cancer Cell · 2018 · 1.2K citations · Full text

Medicine, Immunology, Oncology +17

Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma

Matthew B. Schabath, E A Welsh, William J. Fulp et al. · Oncogene · 2015 · 445 citations

Medicine, Genetics, Oncology +15

Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial

Ben Creelan, Chao Wang, Jamie K. Teer et al. · Nature Medicine · 2021 · 421 citations · Full text

Medicine, Immunology, Oncology +16

Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153

David Waterhouse, Edward B. Garon, Jason C. Chandler et al. · Journal of Clinical Oncology · 2020 · 240 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +16

Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)

David R. Spigel, Michael McCleod, Robert M. Jotte et al. · Journal of Thoracic Oncology · 2019 · 187 citations

Medicine, Oncology, Pharmacotherapy +17